Elbasvir/Grazoprevir Plus Sofosbuvir in Treatment-Naive and Treatment-Experienced Cirrhotic Patients with Hepatitis C Virus Genotype 3 Infection Treated for 8, 12 or 16 Weeks: Final Results of the C-ISLE Study
Journal article published in 2017 by
This paper was not found in any repository, but could be made available legally by the author.
Preprint: archiving allowed
Data provided by